Aberrant high expression of SREBP-1 has been detected in several metabolic diseases, such as diabetes mellitus, NAFLD/NASH, morbid obesity, hyperlipidemia and atherosclerosis [7]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.